Yazar "Ratziu, Vlad" için listeleme
-
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology
Ratziu, Vlad; Yılmaz, Yusuf; Lazas, Don; Friedman, Scott L.; Lackner, Caroline; Behling, Cynthia; Cummings, Oscar W.; Chen, Li; Petitjean, Matthieu; Gilgun-Sherki, Yossi; Gorfine, Tali; Kadosh, Shaul; Eyal, Eli; Sanyal, Arun J. (Wolters Kluwer Medknow Publications, 2024)Background and aims: Antifibrotic trials rely on conventional pathology (CP) despite recognized limitations. We compared single fiber digital image analysis (DIA) with CP to quantify the antifibrotic effect of Aramchol, a ... -
A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Rinella, Mary, E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta; Byrne, Christopher D.; Castro Narro, Graciela E.; Chowdhury, Abhijit; Cortez-Pinto, Helena; Cryer, Donna; Cusi, Kenneth; El-Kassas, Mohamed; Klein, Samuel; Eskridge, Wayne; Fan, Jiangao; Gawrieh, Samer; Guy, Cynthia D.; Harrison, Stephen A.; Kim, Seung Up; Koot, Bart; Korenjak, Marko; Kowdley, Kris; Lacaille, Florence; Loomba, Rohit; Mitchell Thain, Robert; Morgan, Timothy R.; Powell, Elisabeth; Roden, Michael; Romero-Gomez, Manuel; Silva, Marcelo; Prasad Singh, Shivaram; Sookoian, Silvia C.; Spearman, C. Wendy; Tiniakos, Dina; Valenti, Luca; Vos, Miriam B.; Wong, Vincent Wai-Sun; Xanthakos, Stavra; Yılmaz, Yusuf; Younossi, Zobair; Hobbs, Ansley; Villota-Rivas, Marcela; Newsome, Philip N.; NAFLD Nomenclature consensus group (Elsevier, 2023)The principal limitations of the terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. ... -
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, Mary E.; Lazarus, Jeffrey V.; Ratziu, Vlad; Francque, Sven M.; Sanyal, Arun J.; Kanwal, Fasiha; Romero, Diana; Abdelmalek, Manal F.; Anstee, Quentin M.; Arab, Juan Pablo; Arrese, Marco; Bataller, Ramon; Beuers, Ulrich; Boursier, Jerome; Bugianesi, Elisabetta; Byrne, Christopher D.; Castro Narro, Graciela E.; Chowdhury, Abhijit; Cortez-Pinto, Helena; Cryer, Donna R.; Cusi, Kenneth; El-Kassas, Mohamed; Klein, Samuel; Eskridge, Wayne; Fan, Jiangao; Gawrieh, Samer; Guy, Cynthia D.; Harrison, Stephen A.; Kim, Seung Up; Koot, Bart G.; Korenjak, Marko; Kowdley, Kris V.; Lacaille, Florence; Loomba, Rohit; Mitchell-Thain, Robert; Morgan, Timothy R.; Powell, Elisabeth E.; Roden, Michael; Romero-Gómez, Manuel; Silva, Marcelo; Singh, Shivaram Prasad; Sookoian, Silvia C.; Spearman, C. Wendy; Tiniakos, Dina; Valenti, Luca; Vos, Miriam B.; Wong, Vincent Wai-Sun; Xanthakos, Stavra; Yılmaz, Yusuf; Younossi, Zobair; Hobbs, Ansley; Villota-Rivas, Marcela; Newsome, Philip N. (Elsevier, 2023)The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary confounder terms and the use of potentially stigmatising language. This study set out to determine if content experts and patient ... -
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
Anstee, Quentin M.; Lucas, Kathryn J.; Francque, Sven; Abdelmalek, Manal F.; Sanyal, Arun J.; Ratziu, Vlad; Gadano, Adrian C.; Rinella, Mary; Charlton, Michael; Loomba, Rohit; Mena, Edward; Schattenberg, Jörn M.; Noureddin, Mazen; Lazas, Donald; Goh, George B.B.; Sarin, Shiv K.; Yılmaz, Yusuf; Martic, Miljen; Stringer, Rowan; Kochuparampil, Jossy; Chen, Li; Rodriguez-Araujo, Gerardo; Chng, Elaine; Naoumov, Nikolai V.; Brass, Clifford; Pedrosa, Marcos C. (Wolters Kluwer Medknow Publications, 2023)Background and Aims: With distinct mechanisms of action, the combination of tropifexor (TXR) and cenicriviroc (CVC) may provide an effective treatment for NASH. This randomized, multicenter, double-blind, phase 2b study ...
